Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Bifidobacterium lactis MAK16B42L

What does the research say about Bifidobacterium lactis MAK16B42L?

2 health outcomes synthesised

Research on Bifidobacterium lactis MAK16B42L (and closely related strains such as HN019) has been conducted for 2 health outcomes: immune function and bowel regularity. The strongest evidence — based on 4 studies with moderate overall evidence strength — supports a beneficial effect on increasing PMN cell phagocytic capacity, particularly in healthy elderly adults. No consistent effective dose has emerged across studies.

Strongest evidence — The outcome with moderate evidence strength is Increased PMN Cell Phagocytic Capacity. All 4 studies reported beneficial effects, with effect sizes ranging from moderate to large, and 3 of 4 reaching statistical significance. The research focused on healthy elderly adults and healthy adults. No specific dose range was reported across the studies.

Mixed or weaker evidence — The outcome Improved Bowel Movement Frequency has low evidence strength, based on 3 randomized controlled trials. All 3 reported moderate beneficial effects, and 2 of 3 found statistically significant increases in defecation frequency compared to placebo. The evidence base is small and preliminary, with the studies conducted in adults with low defecation frequency or functional constipation.

Effective dose patterns — No consistent effective dose was reported in either synthesis; the available studies did not provide a standardized dose range.

Population insights — For immune function, healthy elderly adults were the most studied population, suggesting potential benefits in this age group. For bowel regularity, the evidence comes from adults with low defecation frequency or functional constipation.

Notable caveats — Both outcomes are based on small numbers of studies (4 and 3 respectively), and the clinical literature is subject to publication bias — null-result studies are less likely to be published. Therefore, conclusions should be considered preliminary.

Frequently asked

  • What is Bifidobacterium lactis MAK16B42L good for according to research?
    Research suggests Bifidobacterium lactis MAK16B42L (and related strains) may support immune function by increasing PMN cell phagocytic capacity — 4 studies all reported beneficial effects, with moderate evidence. It may also improve bowel movement frequency, with 3 small studies showing consistent moderate benefits.
  • What dose of Bifidobacterium lactis MAK16B42L is typically used in studies?
    No specific effective dose was reported in the available research syntheses. The studies used varying doses, but none were identified as a standardized or optimal dose in the aggregated evidence.
  • Who benefits most from Bifidobacterium lactis MAK16B42L?
    For immune function enhancement, healthy elderly adults were the most studied population. For bowel regularity, the research focused on adults with low defecation frequency or functional constipation. These groups showed the most consistent benefits.
  • Are there caveats or limitations in the research on Bifidobacterium lactis MAK16B42L?
    Yes. The evidence base is small (only 4 studies on immune function and 3 on bowel regularity). The clinical literature is subject to publication bias — null results are less likely to be published. Therefore, findings should be considered preliminary.
  • Does Bifidobacterium lactis MAK16B42L help with immune function?
    According to the research, it may help increase PMN cell phagocytic capacity, a measure of immune activity. All 4 studies reported beneficial effects, with moderate evidence strength. However, the evidence is limited and subject to publication bias.
  • Does Bifidobacterium lactis MAK16B42L improve bowel movement frequency?
    Three randomized controlled trials found moderate beneficial effects on bowel movement frequency, primarily in adults with low defecation frequency or functional constipation. Two of the three studies showed statistically significant increases compared to placebo, but the overall evidence strength is low due to the small number of studies.

Most-studied combinations with Bifidobacterium lactis MAK16B42L

most supplement research is combination research
Also studied with:Bifidobacterium lactis HN019 (4)
Back to top